EarliPoint Health receives expanded FDA clearance for autism assessment in children up to age 8.

Read Release →

Insurance Coverage for Autism Testing: What Parents Need to Know

On This Page

Spotting the signs of autism is only the first step. Once a parent decides to pursue a formal evaluation, the next question is almost always the same: How do we pay for this? The answer depends on your insurance plan, your state, and your child’s age, though there are more options than most families realize.

What Federal Law Requires

A federal mandate requires insurance companies in all 50 states to provide coverage for medically necessary autism evaluations and therapies. The Mental Health Parity Act requires insurers to treat behavioral health services on equal terms with physical health services. The critical caveat is that state mandates apply primarily to fully insured plans regulated by your state. If your coverage comes through a large employer’s self-funded plan governed by federal ERISA law, your employer is not required to comply with state autism mandates. Check your Summary Plan Description or call HR to confirm your plan type.

How State Mandates Vary

All 50 states and Washington, D.C., have enacted autism insurance mandates, but the specifics differ widely. Some states impose no age limits on coverage; others cap benefits at age 10 or 16. Some set annual dollar limits; others do not. California, Colorado, Maryland, and New York have no age restrictions, while others are considerably more limited. The National Conference of State Legislatures maintains a state-by-state breakdown worth reviewing before calling your insurer, so you know what to ask for.

What to Do When Coverage Is Denied

Denials are not always final. An appeal should include a letter of medical necessity from the child’s pediatrician, documentation of the developmental concerns that prompted the referral, and any relevant clinical notes. If the appeal fails, families can file a complaint with their state insurance commissioner, and many states have external review processes that allow an independent body to overturn an insurer’s decision. Autism Speaks provides state-by-state guidance on navigating this process.

The School District Route

Under the Individuals with Disabilities Education Act, every public school district must identify and evaluate children who may have a disability affecting learning, at no cost to the family. Parents can submit a written request to their school principal or district special education director, and the district must respond within a set timeframe, typically 60 days. One important distinction to understand: a school-based evaluation determines educational eligibility for an IEP, not a clinical medical diagnosis. Families should pursue both routes simultaneously, as they serve different purposes and neither substitutes for the other.

Medicaid, CHIP, and Waivers

For lower-income families, Medicaid and CHIP cover autism diagnostic evaluations in all 50 states, though eligibility criteria and the range of covered services vary considerably by state. Medicaid waivers extend coverage beyond standard eligibility to include funding for evaluations, therapies, and community-based services. Waitlists can stretch to several years in some states, so families are advised to apply early, even before they are certain they will need the services.

Nonprofit Grants

Autism Care Today, the MyGOAL Autism Grant Program, the Autism Science Foundation, and the National Autism Association all offer direct financial assistance or resource directories for families facing coverage gaps. University-affiliated autism research centers often conduct evaluations at reduced cost as part of ongoing studies.

The Bottom Line

The financial barriers to an autism evaluation are real, but there are also multiple pathways that can help families access care. Insurance mandates, school-based evaluations under IDEA, Medicaid, waivers, and nonprofit grants can all play a role. Families often find it helpful to begin with their pediatrician and then explore options with their insurer and local school district.

Cheryl Tierney, MD, MPH

Chief Medical Officer

Developmental pediatrician, public health advocate, and Chief Medical Officer at EarliPoint Health. Cheryl blends scientific curiosity with real-world passion — as a physician, professor, and mom, she’s committed to turning early autism research into better care and support for families.

Cheryl Tierney, MD, MPH

Chief Medical Officer

Cheryl serves as EarliPoint’s Chief Medical Officer, helping advance early autism research into more accessible care and support for families.

See how EarliPoint fits seamlessly into your clinical workflow.

Jamie Pagliaro brings over two decades of leadership in autism and behavioral health to his role as President and CEO of EarliPoint. Most recently, he served as Chief Operating Officer at Rethink, a leading SaaS provider supporting individuals with autism and developmental disabilities. Under his leadership, Rethink’s behavioral health division became the company’s largest business unit, serving thousands of clinicians and driving scalable, tech-enabled care delivery.

Earlier in his career, Jamie was Executive Director of the New York Center for Autism Charter School, the first public charter school in New York State dedicated to children with autism. At EarliPoint, he leads the company’s mission to bring breakthrough science to the front lines of care—empowering providers, families, and health systems with earlier answers and better outcomes.

Jamie Pagliaro

President & Chief Executive Officer

Dr. Ami Klin is a globally recognized leader in autism research and early detection. As Director of the Marcus Autism Center and Division Chief of Autism and Developmental Disabilities at Emory University School of Medicine, he has dedicated his career to understanding how young children engage with the social world—and how subtle disruptions in attention can signal developmental differences. His pioneering work in eye-tracking science led to the development of EarliPoint™ Evaluation, the first FDA-authorized tool to objectively assess autism in children as young as 16 months.
At EarliPoint, Dr. Klin drives clinical strategy and innovation, ensuring that families and clinicians worldwide have access to timely, science-based insights that enable earlier, more personalized intervention. His career reflects a deep commitment to transforming how society supports children with autism—starting with the earliest signs.

Ami Klin, PhD

Chief Clinical Officer & Co‑Founder